Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPMV Mosaic ImmunoEngineering	$0.54 -40.1%	$0.46	$0.25 ▼ $1.00	$3.89M	-1.18	376 shs	2,686 shs
CVKD Cadrenal Therapeutics	$13.29 -4.6%	$11.80	$6.89 ▼ $22.90	$27.24M	0.93	33,328 shs	35,865 shs
DBV Invesco DB G10 Currency Harvest Fund	$25.41	$25.41	$24.25 ▼ $28.40	$25.41M	0.23	27,852 shs	N/A
ENLV Enlivex Therapeutics	$1.04 -4.6%	$1.26	$0.81 ▼ $2.10	$24.60M	0.8	261,489 shs	295,921 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPMV Mosaic ImmunoEngineering	-40.13%	+7.83%	+45.14%	+97.43%	-47.86%
CVKD Cadrenal Therapeutics	+1.31%	+8.57%	+20.29%	+4.27%	+76.33%
DBV Invesco DB G10 Currency Harvest Fund	0.00%	0.00%	0.00%	0.00%	0.00%
ENLV Enlivex Therapeutics	+0.93%	-0.91%	-13.49%	+15.22%	-12.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPMV Mosaic ImmunoEngineering	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	3.0952 of 5 stars	3.5	3.0	0.0	0.0	3.8	1.7	0.6
DBV Invesco DB G10 Currency Harvest Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	3.2148 of 5 stars	3.5	5.0	0.0	0.0	3.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPMV Mosaic ImmunoEngineering	0.00	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	3.00	Buy	$32.00	140.78% Upside
DBV Invesco DB G10 Currency Harvest Fund	0.00	N/A	N/A	N/A
ENLV Enlivex Therapeutics	3.00	Buy	$10.00	861.54% Upside

Current Analyst Ratings Breakdown

Latest CPMV, CVKD, DBV, and ENLV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPMV Mosaic ImmunoEngineering	N/A	N/A	N/A	N/A	($0.99) per share	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$2.10 per share	N/A
DBV Invesco DB G10 Currency Harvest Fund	N/A	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPMV Mosaic ImmunoEngineering	-$920K	-$0.10	N/A	∞	N/A	N/A	N/A	-822.45%	N/A
CVKD Cadrenal Therapeutics	-$10.65M	-$8.88	N/A	N/A	N/A	N/A	-265.37%	-196.38%	11/6/2025 (Estimated)
DBV Invesco DB G10 Currency Harvest Fund	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)

Latest CPMV, CVKD, DBV, and ENLV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/19/2025	Q2 2025	CPMV Mosaic ImmunoEngineering	N/A	-$0.02	N/A	-$0.02	N/A	N/A
8/11/2025	Q2 2025	CVKD Cadrenal Therapeutics	-$1.60	-$1.87	-$0.27	-$1.87	N/A	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPMV Mosaic ImmunoEngineering	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
DBV Invesco DB G10 Currency Harvest Fund	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPMV Mosaic ImmunoEngineering	N/A	0.01	0.01
CVKD Cadrenal Therapeutics	N/A	3.55	3.55
DBV Invesco DB G10 Currency Harvest Fund	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	7.20	7.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPMV Mosaic ImmunoEngineering	N/A
CVKD Cadrenal Therapeutics	7.92%
DBV Invesco DB G10 Currency Harvest Fund	85.24%
ENLV Enlivex Therapeutics	1.02%

Insider Ownership

Company	Insider Ownership
CPMV Mosaic ImmunoEngineering	80.99%
CVKD Cadrenal Therapeutics	26.09%
DBV Invesco DB G10 Currency Harvest Fund	N/A
ENLV Enlivex Therapeutics	12.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPMV Mosaic ImmunoEngineering	3	7.24 million	1.38 million	Not Optionable
CVKD Cadrenal Therapeutics	4	2.05 million	1.51 million	Not Optionable
DBV Invesco DB G10 Currency Harvest Fund	80	1.00 million	N/A	Not Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable

CPMV, CVKD, DBV, and ENLV Headlines

Recent News About These Companies

Enlivex Therapeutics (ENLV) Expected to Announce Earnings on Friday

August 27 at 2:10 AM | americanbankingnews.com

Enlivex Therapeutics (NASDAQ:ENLV) Earns Buy Rating from D. Boral Capital

August 20, 2025 | americanbankingnews.com

Enlivex stock soars after positive knee osteoarthritis trial data

August 18, 2025 | investing.com

Enlivex Therapeutics announces topline data from Phase I/II trial of Allocetra

August 18, 2025 | msn.com

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

August 18, 2025 | globenewswire.com

Enlivex to Present Key Results from Osteoarthritis Trial

August 14, 2025 | msn.com

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

August 14, 2025 | globenewswire.com

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

July 28, 2025 | globenewswire.com

Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

June 13, 2025 | usatoday.com

Enlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in Barcelona

June 11, 2025 | nasdaq.com

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

June 10, 2025 | globenewswire.com

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 20, 2025 | globenewswire.com

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

April 23, 2025 | globenewswire.com

Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial

April 23, 2025 | msn.com

Enlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee Osteoarthritis

April 23, 2025 | nasdaq.com

Enlivex completed enrollment of patients in Phase II trial of Allocetra

April 22, 2025 | markets.businessinsider.com

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

April 21, 2025 | globenewswire.com

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth?

April 7, 2025 | finance.yahoo.com

Enlivex Therapeutics doses first patient in Phase I trial of Allocetra

April 4, 2025 | markets.businessinsider.com

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

April 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPMV, CVKD, DBV, and ENLV Company Descriptions

Mosaic ImmunoEngineering OTCMKTS:CPMV

$0.54 -0.36 (-40.13%)

As of 08/27/2025 03:21 PM Eastern

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

Cadrenal Therapeutics NASDAQ:CVKD

$13.29 -0.64 (-4.59%)

Closing price 04:00 PM Eastern

Extended Trading

$14.14 +0.85 (+6.43%)

As of 05:11 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Invesco DB G10 Currency Harvest Fund NYSEARCA:DBV

$25.41 0.00 (0.00%)

As of 03/10/2023

PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.

Enlivex Therapeutics NASDAQ:ENLV

$1.04 -0.05 (-4.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.04 +0.00 (+0.48%)

As of 05:37 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time